JP2025515159A5 - - Google Patents
Info
- Publication number
- JP2025515159A5 JP2025515159A5 JP2024565157A JP2024565157A JP2025515159A5 JP 2025515159 A5 JP2025515159 A5 JP 2025515159A5 JP 2024565157 A JP2024565157 A JP 2024565157A JP 2024565157 A JP2024565157 A JP 2024565157A JP 2025515159 A5 JP2025515159 A5 JP 2025515159A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- weight
- rhgaa
- miglustat
- kit according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338601P | 2022-05-05 | 2022-05-05 | |
| US63/338,601 | 2022-05-05 | ||
| US202263399498P | 2022-08-19 | 2022-08-19 | |
| US202263399491P | 2022-08-19 | 2022-08-19 | |
| US63/399,498 | 2022-08-19 | ||
| US63/399,491 | 2022-08-19 | ||
| US202263404475P | 2022-09-07 | 2022-09-07 | |
| US63/404,475 | 2022-09-07 | ||
| US202263414897P | 2022-10-10 | 2022-10-10 | |
| US63/414,897 | 2022-10-10 | ||
| US202263428970P | 2022-11-30 | 2022-11-30 | |
| US63/428,970 | 2022-11-30 | ||
| US202263431920P | 2022-12-12 | 2022-12-12 | |
| US63/431,920 | 2022-12-12 | ||
| US202263434791P | 2022-12-22 | 2022-12-22 | |
| US63/434,791 | 2022-12-22 | ||
| US202363447222P | 2023-02-21 | 2023-02-21 | |
| US63/447,222 | 2023-02-21 | ||
| PCT/US2023/066657 WO2023215865A1 (en) | 2022-05-05 | 2023-05-05 | Methods for treating pompe disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515159A JP2025515159A (ja) | 2025-05-13 |
| JP2025515159A5 true JP2025515159A5 (enExample) | 2026-05-15 |
Family
ID=86692686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024565157A Pending JP2025515159A (ja) | 2022-05-05 | 2023-05-05 | ポンペ病の治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20260041744A1 (enExample) |
| EP (1) | EP4518885A1 (enExample) |
| JP (1) | JP2025515159A (enExample) |
| KR (1) | KR20250007602A (enExample) |
| CN (1) | CN119343147A (enExample) |
| AU (1) | AU2023265155A1 (enExample) |
| CA (1) | CA3252291A1 (enExample) |
| CL (1) | CL2024003377A1 (enExample) |
| CO (1) | CO2024016724A2 (enExample) |
| IL (1) | IL316776A (enExample) |
| MX (1) | MX2024013673A (enExample) |
| TW (1) | TW202400212A (enExample) |
| WO (1) | WO2023215865A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026006625A1 (en) | 2024-06-26 | 2026-01-02 | Amicus Therapeutics, Inc. | Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| WO2009102895A2 (en) | 2008-02-12 | 2009-08-20 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| US11382980B2 (en) | 2013-10-08 | 2022-07-12 | Taiyo Kagaku Co., Ltd. | Oil/fat composition containing polyunsaturated fatty acid |
| JP6851964B2 (ja) * | 2014-09-30 | 2021-03-31 | アミカス セラピューティックス インコーポレイテッド | 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ |
| IL299470B2 (en) * | 2015-12-30 | 2026-05-01 | Amicus Therapeutics Inc | Improved acid alpha-glucosidase for the treatment of Pompe disease |
| CA3019354A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| KR102618519B1 (ko) * | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| CN119113091A (zh) * | 2017-05-15 | 2024-12-13 | 阿米库斯治疗学公司 | 重组人类酸性α-葡萄糖苷酶 |
| WO2020163480A1 (en) | 2019-02-05 | 2020-08-13 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase and uses thereof |
| JP2024506346A (ja) * | 2021-02-11 | 2024-02-13 | アミカス セラピューティックス インコーポレイテッド | 組換えヒト酸性アルファグルコシダーゼ及びその使用 |
-
2023
- 2023-05-05 WO PCT/US2023/066657 patent/WO2023215865A1/en not_active Ceased
- 2023-05-05 KR KR1020247039256A patent/KR20250007602A/ko active Pending
- 2023-05-05 AU AU2023265155A patent/AU2023265155A1/en active Pending
- 2023-05-05 CA CA3252291A patent/CA3252291A1/en active Pending
- 2023-05-05 EP EP23728984.8A patent/EP4518885A1/en active Pending
- 2023-05-05 TW TW112116800A patent/TW202400212A/zh unknown
- 2023-05-05 JP JP2024565157A patent/JP2025515159A/ja active Pending
- 2023-05-05 CN CN202380045183.6A patent/CN119343147A/zh active Pending
- 2023-05-05 IL IL316776A patent/IL316776A/en unknown
- 2023-05-05 US US18/863,111 patent/US20260041744A1/en active Pending
-
2024
- 2024-11-05 MX MX2024013673A patent/MX2024013673A/es unknown
- 2024-11-05 CL CL2024003377A patent/CL2024003377A1/es unknown
- 2024-12-05 CO CONC2024/0016724A patent/CO2024016724A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3031577T3 (en) | Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| TW589174B (en) | Agent for treating high-risk impaired glucose tolerance | |
| CA3236069A1 (en) | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis | |
| JPH0920659A (ja) | 炎症性腹部疾患のためのカッパ−アヘン製剤作働薬 | |
| CA2166730A1 (en) | H2 antagonist-gastrointestinal motility agent combinations | |
| JP2024506346A5 (enExample) | ||
| TW202345833A (zh) | 一種次黃鹼衍化合物在製備治療肺纖維化藥物中的應用 | |
| KR100681360B1 (ko) | 타액분비 촉진용 카르보스티릴 유도체 | |
| EP0707484A1 (en) | H 2? antagonist-alginate-antacid combinations | |
| WO1996030016A2 (en) | Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases | |
| AU715270B2 (en) | Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases | |
| TW202110437A (zh) | 用於酒精誘發之皮膚潮紅之治療及緩解的組成物及方法 | |
| AU2023403087A1 (en) | Venglustat in combination with a strong or moderate inhibitor of cyp3a4 | |
| JPH0352816A (ja) | 腎炎の治療剤 | |
| JP4373671B2 (ja) | マルトオリゴ糖誘導体及びその用途 | |
| CN101757019A (zh) | 用于减肥或治疗代谢综合征的药物组合物 | |
| CN119424460B (zh) | 5-o-甲基维斯阿米醇苷在制备治疗高尿酸血症产品中的应用 | |
| KR20220111620A (ko) | 코비드-19 감염증의 예방 또는 치료용 약제학적 조성물 | |
| KR20010108040A (ko) | 항-ｈｉｖ 감염증제 및 ｈｉｖ 감염증의 치료 방법 | |
| JP2005343886A (ja) | イブプロフェン含有医薬組成物 | |
| WO2025254426A1 (ko) | 엠파글리플로진 및 텔미사르탄을 함유하는 대사이상 관련 지방성 간질환 예방 또는 치료용 약학적 조성물 | |
| US20230143097A1 (en) | Compositions And Methods To Reduce And/Or Dissolve Calcium Deposits In Arterial Walls | |
| WO2026059289A1 (ko) | 육산화사비소를 유효성분으로 포함하는 대사이상 관련 지방간질환 치료 또는 예방용 조성물 | |
| WO2026056858A1 (zh) | 一种含有淫羊藿苷元的抗溃疡性结肠炎药物组合物 | |
| WO1995001784A1 (en) | H2 antagonist-sucralfate-antiflatulent combinations |